Neoadjuvant treatment with Bevacizumab and folfox-6 in patients with liver metastasis from colorectal cancer: Preliminary results of a phase II study

被引：0
|
作者：
Bertolini, F. [1 ]
Malavasi, N. [1 ]
Dealis, C. [1 ]
Zroni, S. [1 ]
Depenni, R. [1 ]
Fontana, A. [1 ]
Sternieri, R. [1 ]
Ponti, G. [1 ]
Luppi, G. [1 ]
Conte, P. [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Modena, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [21] Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
    Bendell, Johanna C.
    Tournigand, Christophe
    Swieboda-Sadlej, Anna
    Barone, Carlo
    Wainberg, Zev A.
    Kim, Jong Gwang
    Pericay, Carles
    Pastorelli, Davide
    Tarazi, Jamal
    Rosbrook, Brad
    Bloom, Joanna
    Ricart, Alejandro D.
    Kim, Sinil
    Sobrero, Alberto F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 239 - 247
  • [22] The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer
    Kataoka, Masato
    Kanda, Mitsuro
    Ishigure, Kiyoshi
    Matsuoka, Hiroshi
    Sato, Yusuke
    Takahashi, Takao
    Tanaka, Chihiro
    Deguchi, Tomohiro
    Shibata, Yoshihisa
    Sato, Mikinori
    Inagaki, Hitoshi
    Matsui, Takanori
    Kondo, Akinori
    Takano, Nao
    Tanaka, Haruyoshi
    Sakamoto, Junichi
    Oba, Koji
    Kondo, Ken
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (02) : 546 - 553
  • [23] Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
    Hebbar, M
    Tournigand, C
    Lledo, G
    Mabro, M
    André, T
    Louvet, C
    Aparicio, T
    Flesch, M
    Varette, C
    de Gramont, A
    CANCER INVESTIGATION, 2006, 24 (02) : 154 - 159
  • [24] A triple combination of Imatinib, Bevacizumab and Cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Pessino, A.
    Andretta, V.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    Sobrero, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 344
  • [25] Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study
    Takao Takahashi
    Yoshihisa Shibata
    Yuichiro Tojima
    Kenji Tsuboi
    Eiji Sakamoto
    Katsuyuki Kunieda
    Hiroshi Matsuoka
    Kazuyoshi Suzumura
    Mikinori Sato
    Tatsushi Naganuma
    Junichi Sakamoto
    Satoshi Morita
    Ken Kondo
    International Journal of Clinical Oncology, 2013, 18 : 335 - 342
  • [26] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, J. A.
    Stuart, K.
    Zhu, A.
    Fuchs, C.
    Bhargava, P.
    Earle, C.
    Blaszkowsky, L.
    Lawrence, C.
    Battu, S.
    Ryan, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [27] Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study
    Takahashi, Takao
    Shibata, Yoshihisa
    Tojima, Yuichiro
    Tsuboi, Kenji
    Sakamoto, Eiji
    Kunieda, Katsuyuki
    Matsuoka, Hiroshi
    Suzumura, Kazuyoshi
    Sato, Mikinori
    Naganuma, Tatsushi
    Sakamoto, Junichi
    Morita, Satoshi
    Kondo, Ken
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (02) : 335 - 342
  • [28] Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer
    Masato Kataoka
    Mitsuro Kanda
    Kiyoshi Ishigure
    Hiroshi Matsuoka
    Yusuke Sato
    Takao Takahashi
    Chihiro Tanaka
    Tomohiro Deguchi
    Yoshihisa Shibata
    Mikinori Sato
    Hitoshi Inagaki
    Takanori Matsui
    Akinobu Kondo
    Nao Takano
    Haruyoshi Tanaka
    Junichi Sakamoto
    Koji Oba
    Ken Kondo
    Annals of Surgical Oncology, 2016, 23 : 1064 - 1064
  • [29] Phase II trial to evaluate combination of folfox6+bevacizumab in initially unresectable liver metastases from colorectal cancer (crc)
    Malavasi, N.
    Dealis, C.
    Depenni, R.
    Zironi, S.
    Bertolini, F.
    Losi, L.
    Gerunda, G. E.
    Colucci, G.
    Luppi, G.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] RESULTS FROM THE CELIM STUDY: CETUXIMAB PLUS FOLFOX6 OR CETUXIMAB PLUS FOLFIRI AS NEOADJUVANT TREATMENT FOR NONRESECTABLE COLORECTAL CANCER LIVER METASTASES
    Koehne, C.
    Gruenberger, T.
    Bechstein, W.
    Hartmann, J.
    Lang, H.
    Lordick, F.
    Herrmann, T.
    Stoehlmacher, J.
    Frilling, A.
    Raab, H.
    Liersch, T.
    Ockert, D.
    Konopke, R.
    Weitz, J.
    Folprecht, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 23
12345